Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rezolute (RZLT – Research Report) and Pfizer (PFE – Research ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Stocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers. Merck & Co ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Pfizer’s adjusted fourth-quarter profit of 63 cents a share beat the FactSet consensus estimate of 47 cents a share. Revenue rose to $17.76 billion from $14.57 billion, and beat the FactSet consensus ...

Pfizer Inc. (NYSE: PFE) reported a strong performance for the fourth quarter of 2024, with revenues reaching $17.8 billion.

Pfizer expects full-year earnings in the range of $2.80 to $3 per share, with revenue in the range of $61 billion to $64 billion. This story was generated by Automated Insights ( ...